Temocillin in cystic fibrosis: a retrospective pilot study.
BACKGROUND
Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.


METHODS
A retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within +/-1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV(1)%, FVC%).


RESULTS
Twenty six patients had received temocillin. Baseline values of FEV(1)% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV(1)% increased by 7.12(11.67)% after TIV (p<0.01) and 6.65(7.62)% after NTIV (p<0.01). There was no significant difference between the IV courses in mean %change in lung function TIV versus NTIV (FEV(1) 0.46% [95%CI: -4.55 to 5.48%]).


CONCLUSIONS
These data suggest equivalence in the lung function outcome of IV antibiotic therapy includingtemocillin versus standard IV antibiotic therapy.
Kent
Lisa
L
Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, Northern Ireland, United Kingdom.
Bradley
Judy M
JM
France
Megan
M
Döring
Gerd
G
Carryn
Stéphane
S
Bradbury
Ian
I
Rendall
Jackie
J
Jones
Andrew
A
Elborn
J Stuart
JS
D000328:Adult; D000617:Aminoglycosides / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D019121:Burkholderia Infections / Q000188:drug therapy* / Q000209:etiology; D016956:Burkholderia cepacia; D015331:Cohort Studies; D018592:Cross-Over Studies; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010406:Penicillins / Q000008:administration & dosage*; D010865:Pilot Projects; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology; D011550:Pseudomonas aeruginosa; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D055815:Young Adult
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D010406:Penicillins; C031367:temocillin